For the majority of traditional pharma companies, 2017 was a tough year. A round of new policies repeatedly challenged and changed the industry status quo. For innovative pharmas, however, it was different story – a year full of hopes and opportunities. Thanks to the steady increase in healthcare need, the introduction of policies favorable to …
A deep dive of the Chinese pharmaceutical industry in 2017 Once again, it is the time to do a deep dive of the Chinese pharmaceutical industry in 2017. Recently, East Money Information has published their latest Chinese top 500 company list for the past year. Among them, 42 pharmaceutical companies have the honor to join …
An overview of the new progress in the pharmaceutical industry in 2017 In this article, I detailed 3 breakthroughs in the pharmaceutical industry in 2017. Breakthrough of “0”: On 2 June 2017, China formally became a member of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), marking …
The Chinese innovative medicine field is marching into a new phase. The number of novel drugs has exploded in the past few years and is riding on a steady upward trend. It is predicted that 15 to 20 new drugs will be approved from 2018 to 2020, at a speed of 4 to 5 per …
Monoclonal antibody drugs, known as the “biological missile”, is emerging at a rapid speed in the recent years. It has sparkled a worldwide interest, and a range of important treatments were born from it, including Rituxan, the first chimeric antibody for treating tumors, Adalimumab, the famous rheumatoid arthritis monoclonal antibody, Avastin, the 2014 global sales …
In the past decade, medication sale has accounted for the majority of the revenue in the Chinese healthcare system, which has become an urgent issue. The Chinese government is under great pressures to bring immediate changes and turn the tide. In the wake of this phenomenon, it is predicted that three major trends will happen, …